GADA Italia

We are a national medical device distribution company.
We build partnerships with suppliers, organizing and developing
their sales & marketing. We serve as
a reference for healthcare by offering reliable
and innovative treatment solutions.

Our solutions

The experience we have gained through many years in the medical device distribution sector allows us to offer a wide range of quality solutions for cardiovascular, dialysis, infusion and intensive care therapy.

CARDIOVASCULAR

We offer specialized devices for cardiac surgery, interventional cardiology, radiology and vascular intervention.

FIELD OF BLOOD

We offer solutions for hemodialysis, laboratory pre-analytics, transfusion.

INTENSIVE CARE, INFUSION MANAGEMENT AND NEUROMODULATION

We distribute a wide range of innovative and quality products for use in the various areas of infusion management and of intensive care: from resuscitation to intensive care therapies, from general surgery to neuromodulation, from point of care testing to devices for the preparation and injection of pharmaceuticals.

A Unique model of quality

Gada Italia has reinvented the traditional relationship between supplier and distributor with the creation of a distinctive Business Model, characterized by the organization of sales & marketing and processes for defining objectives and ways to achieve them.
This Unique Model is based on constant dialogue with supplying partners in order to strengthen the relationship, making it collaborative, transparent and long-term.
The company is certified UNI EN ISO 14001:2015 in regards to environmental management systems and UNI ES ISO 9001:2015 in regards to quality management systems.

Our numbers

+ 0

Hospitals served

+ 0

Products distributed

+ 0

Annual shipments

About Us

Since 1978 we have been working with commitment and passion to distribute cutting-edge medical technologies for health care. In over 40 years we have become the reference point for public and private hospitals, clinics, university centers and purchasing groups.

The latest news

Impella 2.5: safe hemodynamic support in patients undergoing combined PCI and BAV

The Journal of Invasive Cardiology (J INVASIVE CARDIOL 2019;31[3]:52-56) publishes a prospective, non-randomized study about the safety and efficacy of elective use of hemodynamic support by the Impella 2.5 (Abiomed) in patients undergoing combined

The impact of Neovasc Reducer on ischemic burden and myocardial perfusion: the JACC article

Neovasc, partner of GADA and leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory

Impella 2.5: safe hemodynamic support in patients undergoing combined PCI and BAV

The Journal of Invasive Cardiology (J INVASIVE CARDIOL 2019;31[3]:52-56) publishes a prospective, non-randomized study about the safety and efficacy of elective use of hemodynamic support by the Impella 2.5 (Abiomed) in patients undergoing combined

The impact of Neovasc Reducer on ischemic burden and myocardial perfusion: the JACC article

Neovasc, partner of GADA and leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory

STEMI: a study published on Circulation confirms the efficiency of Impella CP on unloading the left ventricle

A new study published on Circulation (Circulation.2019;139:337–346. DOI: 10.1161/CIRCULATIONAHA.118.038269), the outcomes of which have been presented at the AHA congress by prof. Navin K. Kapur (Tufts Medical Center), confirms efficiency and safety of Abiomed Impella CP